Samsung Bioepis submits biologic application of Herceptin biosimilar in U.S.
Samsung Bioepis(CEO/President Han-Seung Ko) is getting ready to target the U.S. market followed by the European one with ‘SB3(generic name: trastuzumab, European name: ontruzant),’ a biosimilar for the treatment of breast cancer.
Samsung Bioepis announced the U.S. Food and Drug Administration(FD...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.